ABBV-744 as a potential therapeutic option for aggressive cancers Secrets
In Section C, contributors will receive ABBV-744 and oral navitoclax. In Section D, contributors will acquire ABBV-744 and ruxolitinib. Individuals will get treatment right until disorder progression or the individuals are unable to tolerate the study drugs.For all movement cytometry experiments, ten,000 cells for each replicate had been analyzed,